Skip to content

Target Activated Clotting Time for anticoagulation during cardiopulmonary bypass

Target Activated Clotting Time for anticoagulation during cardiopulmonary bypass - TACT study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON52711
Enrollment
1010
Registered
2019-02-20
Start date
2019-11-04
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bloodtransfusion packed red blood cel transfusion

Interventions

1010 patients undergoing cardiac surgery with cardiopulmonary bypass are randomized into a group with target ACT >400 seconds or into a group with a target ACT >480 seconds.

Sponsors

Perfusie
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Adult patients undergoing elective cardiac surgery with cardiopulmonary bypass including coronary artery bypass grafting, valve surgery or a combination of both. Informed consent.

Exclusion criteria

Exclusion criteria: re-operations aorta surgery emergency operation minimized extracorporeal circuits deep hypothermia (

Design outcomes

Primary

MeasureTime frame
Overall packed red blood cell transfusion rate during hospitalization.

Secondary

MeasureTime frame
• 12 and 24-hour blood loss assessed by wound drainage • Postoperative hemoglobin values at 1, 12 and 24 hours following surgery • Reoperations due to bleeding • Late tamponade • Transfusion requirements (FFP, platelets, fibrinogen, PCC) • Postoperative hemostatic parameters • Use of preoperative anticoagulant medication • Number of patients who do not reach the target ACT after the first heparin dose • Total heparin and protamine dosing • Postoperative restenosis of grafts • Clotting of the extracorporeal circuit • Thromboembolic events during and following surgery (e.g. venous thrombosis, pulmonary embolism) • Mortality at 30 days, 90 days and 1 year following surgery • Patient demographics

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)